Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07784296
Recruiting Observational

Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension

NCT07784296 · tracked via the Priya Life Science South Korea tracker
Sponsor
Hanmi Pharmaceutical Company Limited
Phase
Observational
Started
2026-03-19
Last updated
2026-08-25

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

AMOPREL TAB 1.67/16.67/4.17mg

AMOPREL TAB 1.67/16.67/4.17mg: Follow-up of subjects prescribed medication in a non-intervention study

Study summary

A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Korean patients aged 19 years or older diagnosed with hypertension 2. Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug 3. Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment 4. Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study Exclusion Criteria: 1. Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab. 2. Pregnant women, women who may be pregnant, and nursing mothers 3. Individuals currently participating in an interventional study 4. Individuals deemed unsuitable for participation in this study by the researcher for other reasons

Primary outcome measure(s)

  • The change in Systolic Blood Pressure (SBP) relative to baseline — the 6-month time

Trial sites (1)

FacilityCityRegionStatus
Yongin Severance Hospital Gyeonggi-do South Korea Recruiting

More Hanmi Pharmaceutical Company Limited trials in South Korea

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors Recruiting
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin Recruiting
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors Recruiting
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension Starting soon
A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers Starting soon

Other trials for the same condition

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 Starting soon
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Starting soon
Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT) Recruiting
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07784296 on ClinicalTrials.gov ↗ ← All trials in South Korea